Loading
BRCA1 breast cancers seem to grow from cells driven by the RANK signal. Denosumab blocks it and is already used for bone. A trial is testing whether it prevents these cancers.
BRCA1 breast cancers appear to grow from progenitor cells driven by RANKL signalling, and denosumab, already used for bone, blocks it, so this idea supports completion of the ABCSG BRCA-P trial, which randomises BRCA1 carriers to denosumab or placebo with breast cancer incidence as the endpoint, and prepares implementation pathways for a positive result. Preclinical and window-of-opportunity data show reduced proliferation in carrier breast tissue. The test is the BRCA-P readout followed, if positive, by an implementation study with uptake and adherence endpoints. Being tested at scale, it addresses the bottleneck Inherited risk is mostly unidentified and links to chemoprevention, BRCA and TNBC.
One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
For women who carry a BRCA mutation, preventive removal of the ovaries and tubes saves lives, and preventive mastectomy almost eliminates breast cancer. These are the strongest prevention effects in oncology, which is why finding carriers before they develop cancer matters so much.
Shares PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers, National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Chemoprevention & risk-reducing surgery, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers.
Shares PROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD).
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD).
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD).
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Chemoprevention & risk-reducing surgery, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified.
Shares National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer, Inherited risk is mostly unidentified.